Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bassam Baroudi

Cardiovascular Disease Gulfport, MS Medical Doctor

NPI 1487683231 CMS profile 294479

4215 15Th St, Gulfport, MS 39501

Open in the dashboard

General payments

$6,860

281 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bassam Baroudi of Gulfport, MS is reported in the CMS Open Payments database as having received $6,860 across 281 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $471 23
2024 General $970 41
2023 General $651 28
2022 General $1,278 56
2021 General $820 39
2020 General $1,339 32
2019 General $1,330 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bassam Baroudi
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Bassam Baroudi were reported at $471. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Bassam Baroudi Cardiovascular Disease median Middle half National median
2019 $1,330 $450 $127–$1,392 $163
2020 $1,339 $242 $77–$751 $114
2021 $820 $335 $101–$1,037 $132
2022 $1,278 $395 $121–$1,211 $149
2023 $651 $443 $136–$1,283 $160
2024 $970 $450 $136–$1,323 $164
2025 $471 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biotronik Inc. $892 12 payments
  2. Abbott Laboratories $818 24 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $628 37 payments
  4. Pfizer Inc. $446 28 payments
  5. Janssen Pharmaceuticals, Inc $345 21 payments
  6. Shockwave Medical, Inc $288 4 payments
  7. Novartis Pharmaceuticals Corporation $273 17 payments
  8. Abiomed $271 9 payments
  9. E.R. Squibb & Sons, L.L.C. $240 16 payments
  10. Amgen Inc. $219 15 payments
  11. Other $2,440 98 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,181 278 payments
  2. Travel and Lodging $604 2 payments
  3. Gift $75 1 payment
Products named General payments · program years 2019–2025
  1. LifeVest $628 37 payments
  2. Optis Coronary Imaging System $385 3 payments
  3. XARELTO $345 21 payments
  4. ELIQUIS $333 22 payments
  5. Impella $271 9 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $226 2 payments
  7. Repatha $219 15 payments
  8. NEXLETOL $211 8 payments
  9. PRALUENT $181 7 payments
  10. WATCHMAN Access System $171 2 payments
  11. Other $3,493 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$202,901

Medicare's payments for the services billed

Medicare patients

615

Average age 76

Services billed

4,032

345 women, 270 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 55%
Diabetes 41%
Atrial fibrillation 38%
Heart failure 36%
Chronic kidney disease 34%
Depression 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kcentra
  • CSL Behring $122
$122 — —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $104
$104 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $46
$46 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $39
$39 — —
ELIQUIS
  • PFIZER INC. $17
  • E.R. Squibb & Sons, L.L.C. $16
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record